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ADVISORY COUNCIL ON THE MISUSE OF DRUGS 
Home Office, 2 Marsham Street, London SW1P 4DF 
 _______________________________________________________ 
 
 
 
April 2007 
 
Dear Home Secretary 
 
In January 2006 your predecessor asked the Advisory Council on the Misuse of Drugs 
(ACMD) to look into the factors surrounding drug facilitated sexual assault.  The 
Council has now done so and I am pleased to enclose its report.   
  
The Council considers drug facilitated sexual assault, whether premeditated or 
opportunistic, to be a particularly disgusting offence.  It makes a number of 
recommendations including: 
 
1)  A proposal for the ACMD to examine measures for restricting the availability of 
gamma butyrolactone (GBL) and 1, 4-butanediol. 
 
2)  A request that the Association of Chief Police Officers, in consultation with the 
Forensic Science Service, issue further advice to ensure appropriate body samples are 
collected from victims as soon as possible after an alleged attack. 
 
3)  A request that the Department of Health arranges for "early evidence kits", and 
appropriate advice on their use,  to be made available in all Accident and Emergency 
Departments and Sexual Assault Referral Centres. 
 
4) Further advice should be offered to young people about how to minimise the risks 
of drug facilitated sexual assault. 
  
The Council will keep this matter under review and will make further reports as is 
appropriate. 
  
Yours sincerely 
  
 
Professor Sir Michael Rawlins FMedSci 
Chairman  
 
 
 Advisory Council on the Misuse of 
Drugs 
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1. Background 
 
1.1 The Advisory Council on the Misuse of Drugs is established under the 
Misuse of Drugs Act. (1971) and its terms of reference and current 
membership are shown in Annexes 1 and 2 (respectively).  In January 
2006, the then Home Secretary requested the Council to report on drug 
facilitated sexual assault.   
 
1.2 Two forms of serious sexual assault are now defined in law (1).  Rape 
refers to penetration of the vagina, anus (since 1994) or mouth (since 
2003) by an assailant’s penis without consent.  Assault by penetration 
is penetration of the vagina or anus by other body parts (such as 
fingers) or by objects.  
 
1.3 The 2001 British Crime Survey included a self-completed questionnaire 
involving a representative sample of 22,463 women and men aged 16 
to 59 years (2).  The questionnaire was designed to ascertain the most 
reliable estimates of the incidence of domestic violence, sexual assault 
and stalking for England and Wales. 
 
1.3.1 The results (2) showed that, amongst the age range of 16 to 59 years, 
7.0% of women and 1.5% of men had been subjected to a serious 
sexual assault during their lives; and that 1.5% of women and 0.1% of 
men had been the subject of a serious sexual assault in the previous 
year.  Extrapolated to the population of England and Wales these 
findings suggest that, during 2000, there were around 25,000 victims of 
rape (95% confidence intervals 11,000 to 39,000). 
 
1.3.2 Of those respondents who had been subjected to serious sexual 
assault, 40% told no-one about their ordeal and in only 12% of 
instances did the police come to know about it (2). 
 
1.4 The number of prosecutions for rape in 2004 was 2689 of which only 
751 resulted in conviction (3). 
 
2 Drug facilitated sexual assault: overview 
2.1 Over the past ten years there have been increasing numbers of reports 
from Australia (4,5,6), the United States of America (7,8), the United 
Kingdom (9,10) as well as elsewhere in Europe expressing concern 
about the frequency with which drugs and/or alcohol have been used to 
induce people to engage in sexual activity without their consent.   
 
2.2 The 2001 British Crime Survey (2) showed that of those who had ever 
been subjected to a serious sexual assault, 5% stated that they had 
undergone vaginal or anal penetration with a penis whilst drugged in 
some way; and 15% admitted to penetrative sexual activity whilst 
incapable of giving consent due to alcohol.  A further 6% had been 
subjected to penetration of the mouth, or other assault by penetration, 
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whilst drugged; and 17% when incapable of giving consent due to 
alcohol. 
 
2.3 A number of terms have been used to describe situations where drugs 
and/or alcohol have been used to induce people to engage in sexual 
activity without their consent (2).  These terms include “date rape”, 
“date rape drugs” and “spiked drinks”.   
 
2.3.1 In this report, the Council’s definition of drug facilitated sexual assault 
includes all forms of non-consensual penetrative sexual activity 
whether it involves the forcible or covert administration of an 
incapacitating or dysinhibiting substance by an assailant, for the 
purposes of serious sexual assault; as well as sexual activity by an 
assailant with a victim who is profoundly intoxicated by his or her own 
actions to the point of near or actual unconsciousness.   
 
2.3.2 This definition does not distinguish between the use of controlled 
drugs, and other substances (including alcohol), that may induce 
people to engage in penetrative sexual activity without their consent; 
nor does it distinguish between forced, covert or self-administration. 
 
2.4 The 2001 British Crime Survey clearly suggests that the prevalence of 
drug facilitated sexual assault is significant. The records of convictions 
for serious sexual assault, however, do not differentiate between those 
concerned with drug facilitated sexual assault and those involving other 
forms of force. 
 
2.4.1 The low reporting rates, to the police, by victims of serious sexual 
assault are likely to be even lower than for those subjected to drug 
facilitated sexual assault.  The reasons include (7): 
• feelings of guilt or self-blame because of prior voluntary 
ingestion of alcohol and/or drugs; 
• confusion and uncertainty, as a result of memory impairment 
due to the drug’s effects, about what happened; 
• reluctance to make accusations without personal knowledge, or 
memory, of the circumstances leading to the assault. 
 
3. Drug facilitated sexual assault: the drugs 
 
3.1 Two groups of drugs – central nervous system depressants and central 
nervous system stimulants – have been implicated, in the literature, 
with drug facilitated sexual assault.    
 
3.1.1 The intended effect of administering central nervous system 
depressants (sedatives and hypnotics), in drug facilitated sexual 
assault, is to alter a victim’s behaviour and cause anterograde amnesia 
(i.e. loss of memory for the events leading up to the assault).  The 
behavioural change may range from acquiescence (as a result of drug-
induced dysinhibition) to unconsciousness.    
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3.1.2 Emerging evidence also suggests that, paradoxically, at least some 
substances with central nervous system stimulant activity may also 
cause dysinhibition leading to inappropriate or more risky 
acquiescence in sexual activity (11).   
 
3.2 The central nervous system depressant substances that have been 
most frequently associated with drug facilitated sexual assault in the 
international literature are alcohol, benzodiazepines, gamma-hydroxy 
butyrate (and related substances), and ketamine. 
 
3.2.1 Alcohol, depending on the quantity consumed, will produce (12) effects 
ranging from dysinhibition (at low doses) to unconsciousness (at high 
doses). The potential of alcohol to be a causal agent in drug facilitated 
sexual assault is unquestionable irrespective as to whether it has been 
consumed knowingly, or unknowingly, by a victim. 
 
3.2.2 Benzodiazepines, generally, are all central nervous system 
depressants. They are used, clinically, as hypnotics, sedatives, 
anxiolytics and anticonvulsants.  They are also recognised to produce 
dysinhibition at doses that do not result in stupor (13). All are controlled 
under the Misuse of Drugs Act (1972) as class C substances.    
 
The benzodiazepine most commonly claimed to be associated with 
drug facilitated sexual assault in the media is flunitrazepam (Rohypnol) 
which is licensed in many countries as a hypnotic.  Although available 
on private prescription in the UK, it is not provided under the National 
Health Service.  Flunitrazepam is tasteless, odourless and colourless 
and readily dissolves in liquid.  After administration it is slowly 
metabolised, and it (or its metabolites) can be detected in the urine for 
at least 72 hours.   It has been implicated in drug facilitated sexual 
assault in the US and Britain.  The manufacturer of the licensed 
product (Roche Pharmaceuticals) undertook reformulation, in 1998, 
and added a blue dye which fizzes when it comes into contact with 
liquids.   This dye is not, however, present in flunitrazepam from illicit 
sources.   The UK law enforcement agencies report 31 seizures of illicit 
flunitrazepam between 2001 and 2006. 
 
There is no reason to believe that flunitrazepam has unique properties 
as a weapon in drug facilitated sexual assault: all other 
benzodiazepines, as well as non-benzodiazepines with similar 
pharmacological properties (zaleplon, zopiclone, zolpidem), have 
dysinhibitory properties. 
 
3.2.3 Gamma-hydroxy butyrate (GHB) is a central nervous system 
depressant with a mechanism of action that differs from those of either 
alcohol or the benzodiazepines (14). It produces sedation and 
anaesthesia but has a steep dose-response curve that is very variable 
between individuals.  High blood concentrations may cause stupor and 
respiratory depression: low doses are associated with increased libido, 
euphoria, suggestibility, passivity and amnesia which are properties 
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rendering victims vulnerable to non-consensual sexual activity.  GHB is 
rapidly absorbed with peak plasma concentration achieved between 30 
and 45 minutes.  It is rapidly metabolised, with a half-life of around 30 
minutes, and is undetectable in urine after 12 hours.   It may be 
possible to detect the compound for very much longer in hair.   
 
GHB has been licensed in Europe as an anaesthetic agent and alcohol 
substitute for some years and is now authorised as a medicinal product 
in the UK (as sodium oxybutrate) for sleep fragmentation in narcolepsy; 
and it has been controlled under the Misuse of Drugs Act as a class C 
substance since 2003.   GHB has been implicated in sexual assaults in 
the UK, other parts of Europe, and the US (9).   The law enforcement 
agencies report 233 seizures of GHB between 2001 and 2006. 
 
3.2.4 Gamma butyrolactone (GBL) and 1, 4-butanediol (1,4-B) are 
interconvertible forms of GHB that are  rapidly metabolised to GHB 
after ingestion.  They therefore produce effects that are identical to 
those of GHB.   GBL is commonly used as a cleaning fluid and as an 
industrial solvent.  It is also used as a precursor in the chemical 
synthesis of GHB.   GBL is not currently controlled under the Misuse of 
Drugs Act.   
 
1,4-B is also used as a cleaner and as an industrial solvent, but also in 
the manufacture of plastics.  Like GBL it is not currently controlled 
under the Misuse of Drugs Act.   Both GBL and 1,4-B appear in the 
urine as GHB.  Law enforcement agencies are aware of substantial 
exports of GBL from the UK to the US where both are controlled 
substances. 
 
3.2.5 Ketamine has been available since the 1960s as an anaesthetic agent 
and is a licensed medicinal product in the UK.  It acts by blocking the 
action of glutamate and, at low doses, produces euphoria coupled with 
feelings of dissociation (15).  It has been implicated as a weapon in 
drug facilitated sexual assault and has been controlled under the 
Misuse of Drugs Act, as a class C substance, since 1st January 2006.   
 
3.3 The central nervous system stimulants most commonly associated with 
drug facilitated sexual assault are cocaine and MDMA (ecstasy).  
 
3.3.1 Cocaine is a local anaesthetic and central nervous system stimulant 
that is administered as either the hydrochloride salt or the [free]-base. 
The salt is taken either intranasaly (snorted) or via other mucus 
membranes (such as by rubbing on the gums, vagina or anus) or is 
dissolved and then injected. The free base forms (including “crack”) are 
smokable and give a very fast and intense “high”.  Methylamphetamine 
is a smokable derivative of amphetamine that is widely abused in the 
Far East and the USA but has limited use in the UK.  When smoked a 
long lasting “high” is produced.  It is thought that cocaine and 
methylamphetamine cause the release of dopamine in the frontal brain 
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leading to an increase in sexual drive, as well as loss of inhibitions, so 
encouraging risky sexual behaviour.  
 
3.3.2 MDMA (ecstasy) is a stimulant that has a different profile of action to 
cocaine and methylamphatamine in that it probably releases serotonin 
as well as dopamine. It is very widely used as a dance drug because of 
its ability to energise as well as increase empathy and positive feelings 
towards others. There are anecdotal reports of its use being associated 
with increased sexual activity, though usually in a consensual manner.   
 
 
4. Drug facilitated sexual assault: UK forensic experience 
 
4.1 Two studies, carried out by the Forensic Science Service (16) and the 
Police Standards Unit (17), have recently been published.  That of the 
Forensic Science Service (16) describes the toxicological findings in 
1014 instances of alleged drug facilitated sexual assault for the period 
2000 to 2002.  Operation Matisse (17) was a 12 month study by the 
police, the Forensic Science Service and the Sexual Assault Referral 
Centres, in 6 areas of England.  It investigated 120 police-referred 
victims who had reported a drug facilitated sexual assault within the 
previous 72 hours.  Victims completed a questionnaire and provided 
samples of blood and urine (and, in some instances, hair) which were 
examined for the presence of alcohol and a wide range of licit and illicit 
drugs. 
 
Forensic Science Service Study (16) 
 
4.2 Alcohol, alone or with an illicit drug and/or medicinal drug, was present 
in 46% of cases.   Illicit drugs were detected in 34%; cannabis (26%), 
cocaine (11%) and MDMA (5%) were the most common.  GHB was 
detected in 2 cases. 
 
4.2.1 In those instances where alcohol was detected, back extrapolation 
suggested that, at the time of the alleged incident, 60% had levels in 
excess of 150 mg/100ml and 40% had levels above 200 mg/100ml. 
Levels above 150 mg/ml are associated with intense intoxication and 
memory impairment.  
 
4.2.2 A range of benzodiazepines and other central nervous system 
depressants were identified in the samples examined.  In 21 instances, 
their presence could not be explained by voluntary use.  The drugs 
involved are shown in table 1. 
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Table 1: Unexplained drugs with central nervous system activity 
identified in blood or urine samples 
 
Number attributed to deliberate “spiking” Drug 
Scott-Ham and Burton 
(n=1,014) 
Operation Matisse 
(n=120) 
Temazepam 6 1 
Diazepam 3 1 
Lorazepam 1 0 
Lormetazepam 1 0 
Nitrazepam 1 0 
Flunitrazepam 1 0 
Zopiclone 0 0 
Diphenhydramine* 2 0 
Mirtazapine 1 0 
GHB 2 2 
MDMA 3 1 
Cocaine 0 2 
Cocaine plus cannabis 0 2 
* This is an antihistamine that will cause sedation and accentuate the actions 
of alcohol  
 
4.2.3 There were a further 9 instances where the victim was allegedly 
offered, or forced to ingest, a drug.  The substances involved included 
benzodiazepines or benzodiazepine-like substances (n=5) and cocaine 
(n=2). 
 
Operation Matisse (17) 
 
4.3 Although in 119 out of 120 cases alcohol had allegedly been taken 
before the offence, it could be detected in only 62 (52%) instances. 
There were marked time delays, between the incident and sample 
collection, where victims stated that alcohol had been consumed but 
none was detected.  
 
4.3.1 In 41 of the 62 instances where alcohol was detected one or more 
controlled drugs were also present. 
 
4.3.2 In those cases where alcohol levels could be back-extrapolated to the 
time of the alleged incident (n=31), all had levels in excess of 
100mg/100ml and 22 had levels in excess of 200 mg/100ml. 
 
4.4 In 9 instances, drugs which victims stated they had not used, were 
identified in body fluids (Table 1).  In one case (not included in Table 1) 
the victim was forced to take cocaine. 
 
4.4.1 In a further 11 instances, the covert administration of drugs could not 
be eliminated due to lack of clarity in circumstantial information.  The 
drugs involved included cocaine (4 cases) and alcohol (3 cases), as 
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well as “Night Nurse”, dextropropoxyphene, codeine plus 
diphenhydramine and zopiclone (1 each). 
 
4.5 Beer mats/coasters impregnated with materials designed to help in the 
detection of drugs that are used as weapons in drug facilitated sexual 
assault - so called "drug detectors" – are useful for raising awareness; 
but should not be relied on as they only test for a limited range of drugs 
and can give misleading results. 
 
 
5. Conclusions 
 
5.1 Drug facilitated sexual assault, including with alcohol, is a significant 
problem in Britain and the Council recognises two forms (17): 
 
• Proactive drug facilitated sexual assault involves the covert or 
forcible administration of an incapacitating or dysinhibiting 
substance, by an assailant, for the purpose of sexual assault. 
 
• Opportunistic drug facilitated sexual assault involves sexual activity, 
by an assailant, with a victim who is profoundly intoxicated by his or 
her own actions to the point of near or actual unconsciousness, and 
thus lacks the capacity to consent. 
 
5.2 The incidence of drug facilitated sexual assault is unclear.  Many 
victims fail to report the incident for reasons discussed above.  Where 
victims do report the incident, the elapsed time may be too long for 
drugs to be reliably detected in blood or urine.  This particularly applies 
to alcohol and GHB. 
 
5.3 The evidence suggests that the most common weapon used in drug 
facilitated sexual assault, whether proactive or opportunistic, is 
probably alcohol.   
 
5.4 Although no case of drug facilitated sexual assault using flunitrazepam 
was identified in either the Forensic Science Services study, or in 
Operation Matisse, other benzodiazepines appear to have been used 
as weapons. 
 
5.5 Other controlled drugs – especially cocaine and GHB – appear to have 
been used as weapons in some instances of drug facilitated sexual 
assault. 
 
 
6. Recommendations 
 
6.1 The Council considers drug facilitated sexual assault to be no less 
coercive as forcible sexual assault: both remove the capacity to 
consent.  The Sexual Offences Act (2003) makes it an offence to 
administer any drug with intent to stupefy or overpower a person so as 
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to commit a sexual offence against them.   Although this provision 
covers proactive drug facilitated sexual assault it fails to provide 
protection against opportunistic drug facilitated sexual assault.   The 
Council is uncertain as to whether the law could be strengthened in this 
respect, but recommends that the Home Secretary seeks advice from 
the Government’s law officers. 
 
6.2 Apart from alcohol, those substances most frequently implicated in 
drug facilitated sexual assault are already adequately controlled under 
the Misuse of Drugs Act.   Nevertheless, the Council is concerned at 
the continuing availability of gamma butyrolactone (GBL) and 1,4-
butanediol (1,4-B) which are not controlled.  It proposes to re-examine 
the use of these materials, and will provide the Home Secretary with 
further advice before the end of this year. 
 
6.3 The Association of Chief Police Officers, in consultation with the 
Forensic Science Service, should issue further advice to ensure that 
appropriate samples of blood and urine are obtained from potential 
victims of drug facilitated sexual assault, at the earliest possible time, 
using the “early evidence kit” or other appropriate sampling techniques.  
In particular, this advice should emphasise that the collection of urine 
samples should not await the arrival of a forensic medical examiner.  
Advice on the collection of hair samples should also be included. All 
samples should be saved and tested for alcohol as well as drugs. 
 
6.4 The Department of Health should ensure that “early evidence kits” are 
available in all Accident and Emergency Departments.  The 
Department of Health should also consider developing, and 
disseminating, guidance to staff in Accident and Emergency 
Departments and Sexual Assault Referral Centres, to improve the 
management of victims of alleged drug facilitated sexual assault.  
Health ministers may wish to ask the National Institute for Health and 
Clinical Excellence (NICE) to develop such guidance. 
 
6.5 Further efforts should be made to alert young people to the ways in 
which the risk of drug facilitated sexual assault can be minimised.  
Such advice should be particularly targeted through secondary schools 
as well as further and higher educational establishments and should 
include, as appropriate, the following messages: 
• Plan your journey both to and from home. 
• Avoid going to a club, pub or party alone. 
• Make sure somebody knows where you are going and what time 
you will be back. 
• Stay aware of what is happening around you and avoid situations 
in which you feel uncomfortable. 
• Don’t accept a drink from anyone you don’t trust. 
• Don’t share or exchange drinks. 
• Don’t leave your drink unattended even when going to the toilet.  
Take it with you. 
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• Consider carefully whether to leave a party, club or pub with 
someone you’ve only just met. 
• Be a friend by watching out for others, and be aware of any 
changes in their behaviour. 
 
6.6 The public should be warned that so-called “drug detectors” (see 
paragraph 4.5), using beer mat tests, cannot be relied on to warn 
potential victims of the range of possible weapons used in drug 
facilitated sexual assault. 
 
6.7 Further research in the area should be promoted.  The Forensic 
Science Service should be encouraged to update the study by Scott-
Ham and Burton (16).  The British Crime Survey should be asked to 
repeat its 2001 study especially in respect of those parts of their 
questionnaire concerned with serious sexual assault. Convictions for 
drug facilitated sexual assault should also be recorded. 
 
6.8 The Council will continue to keep this issue under review. 
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Annex 2 
 
Terms of Reference of the Advisory Council on the Misuse of Drugs 
 
“ It shall be the duty of the Advisory Council to keep under review the situation 
in the United Kingdom with respect to drugs which are being or appear to 
them likely to be misused and of which the misuse is having or appears to 
them capable of having harmful effects sufficient to constitute a social 
problem, and to give to any one or more of the Ministers, where either Council 
consider it expedient to do so or they are consulted by the Minister or 
Ministers in question, advice on measures (whether or not involving alteration 
of the law) which in the opinion of the Council ought to be taken for preventing 
the misuse of such drugs or dealing with social problems connected with their 
misuse, and in particular on measures which in the opinion of the Council, 
ought to be taken:  
  
a)         for restricting the availability of such drugs or supervising the 
arrangements for their supply; 
 
b)         for enabling persons affected by the misuse of such drugs to obtain 
proper advice, and for securing the provision of proper facilities and services 
for the treatment, rehabilitation and after-care of such persons; 
  
c)         for promoting co-operation between the various professional and 
community services which in the opinion of the Council have a part to play in 
dealing with social problems connected with the misuse of drugs; 
  
d)         for educating the public (and in particular the young) in the dangers of 
misusing such drugs and for giving publicity to those dangers; and  
  
e)         for promoting research into, or otherwise obtaining information about, 
any matter which in the opinion of the Council is of relevance for the purpose 
of preventing the misuse of such drugs or dealing with any social problem 
connected with their misuse”.  
  
A further duty is placed on the Council by the Act to consider any matter 
relating to drug dependence or the misuse of drugs which may be referred to 
them by any one of the Ministers concerned, and in particular to consider and 
advise the Home Secretary on any communication which he refers to the 
Council which relates to the control of a dangerous or otherwise harmful drug 
and which is made to Her Majesty’s Government by any organisation or 
authority established by treaty, convention or other agreement or arrangement 
to which Her Majesty’s Government is a party. 
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